Hybrid Program | TBD CE/CME Credits

The 7th Annual Best of Breast conference will take place on February 22, 2025. This innovative and state of the art hybrid program was set in a multidisciplinary tumor board environment featuring some of the world's leading breast cancer experts to discuss cases beginning with high-risk characteristics, adjuvant and metastatic treatment advances, interdisciplinary care, and survivorship and recurrence—all while incorporating data from the major oncologic annual meetings.

Conference Agenda
Saturday, February 22, 2025

8:35 AM
Welcome and Exhibits

8:55 AM
Opening Remarks

9:00 AM
Non CME Presentation

9:45 AM
Neo-Adjuvant Systematic Therapy for HR+ Breast Cancer: Which Agents, When and for How Long?

10:10 AM
Genetic Testing and Management of Breast Cancer Susceptibility Germline Mutations

10:35 AM
Break and Exhibits

10:55 AM
Advanced Stage Hormone Positive Breast Cancer: Fine-Tuning Sequential Endocrine and Targeted Therapy

11:20 AM
Monday morning Ptacice Implications: Q&A and Case Discussion

12:05 PM
Break and Exhibits

12:15 PM
Non CME Presentation

1:00 PM
Antibody Drug Conjugates: Present and Future Applications in Breast Cancer

1:25 PM
Genetic Testing and Management of Breast Cancer Susceptibility Germline Mutations

1:50 PM
Break and Exhibits

2:00 PM
Neo and Adjuvent Therapy for Triple Negative Breast Cancer: Optimizing and Right-Sizing

2:25 PM
Monday morning Practice Implications: Q&A and Case Discussion

3:10 PM
Adjourn

Agenda Subject To Change. All times are EST.

• Learning Objectives

  • Apply the current standards of oncology care and key updates from national clinical guidance pathways to optimize the management of patients with various hematologic malignancies.

  • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.

  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.

• Accreditation Information | TBD CE/CME Credits

  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Nurses (ANCC) Credit Designation

  Amedco LLC designates this activity for a maximum of TBD ANCC contact hours.

  Physicians (ACCME) Credit Designation

  Amedco LLC designates this live activity for a maximum of TBD AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

  Amedco LLC designates this activity for a maximum of TBD knowledge-based CPE contact hours.

  NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources

  • Catered meals through-out the program